Eisai Reports Results of Lenvima (lenvatinib) + Everolimus in P-II 218 Study for Advanced Renal Cell Carcinoma

November 9, 2020 Auto Bot 2020, Advanced Renal Cell Carcinoma, Clinical Trials, Eisai, Lenvima, P-II, Presents, results, Study 0

Shots:

  • The P-II 218 study involves assessing Lenvima (14mg, qd) + everolimus (5mg, qd) vs Lenvima (18mg, qd) + everolimus (5mg qd) in patients with clear-cell RCC, following treatment with an anti-angiogenic therapy, with prior anti-PD-1/PD-L1 therapy permitted
  • In the primary analysis, @24wks. ORR (32.1% vs 34.8%) i.e. lower dose did not meet the threshold for non-inferiority; Grade 2/ any ≥ Grade 3 TEAEs (82.8% vs 79.6%); discontinuation (32.4% vs 26.8%); dose interruption (74.6% vs 83.3%); dose reductions (67.6% vs 69.6%)
  • Overall ORR (34.6% vs 40.6%); mPFS (11.1 vs 14.7mos.); m-OS (27.0 vs NE). Results were presented at IKCS 2020

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Welwyn Hatfield Times

The post Eisai Reports Results of Lenvima (lenvatinib) + Everolimus in P-II 218 Study for Advanced Renal Cell Carcinoma first appeared on PharmaShots.